Expert networks provide brief consultations, typically hour-long calls for perspective gathering. Alacrita's model is fundamentally different: our consultants work for Alacrita on defined project assignments where they contribute materially to deliverables. Your contract is with Alacrita, and we take responsibility for quality and delivery throughout the engagement. We do not offer one-hour consults. Our consultants are former biotech and pharma operators with 25+ years average experience who are integrated into project teams, not made available for ad-hoc calls.

Our consultants typically bring 25+ years of experience in their respective fields. These are former CMOs, VP Regulatories, heads of CMC, medical directors, and other senior operators who held positions at biotech and pharma companies before joining our network. The network includes 96+ MDs globally, 55 of whom are CMO-caliber physician executives. Every consultant has held the positions they are now consulting on.

Alacrita's core team matches consultants based on the specific requirements of each engagement, including therapeutic area, product modality, functional discipline, development stage, and regulatory geography. With 350+ consultants spanning 29 functional disciplines, 22 disease areas, and 18 product modalities, we can assemble teams with precisely relevant experience. The core team manages project delivery, quality, and client communication throughout.

Yes. This is one of the core advantages of Alacrita's model. Rather than engaging separate boutique firms for regulatory, CMC, clinical, and commercial expertise, clients can access all of these disciplines through a single relationship with Alacrita. Our core team coordinates across specialists to ensure integrated recommendations rather than conflicting advice. This is particularly valuable for due diligence, development strategy, and programs that span multiple functional areas.

Yes. Our consultants provide both strategic guidance and hands-on execution. This includes writing protocols, preparing regulatory submissions, developing CMC dossiers, managing clinical operations, and serving in interim leadership roles such as CMO or VP Regulatory. Our engagement types range from focused project work to extended interim leadership placements. Alacrita remains accountable for delivery throughout.

The network covers 22 therapeutic areas including oncology (209+ specialists), autoimmune/immunology, CNS, rare diseases, infectious disease, cardiovascular, respiratory, and hematology. Product modality coverage spans 18 categories including small molecules, antibodies and ADCs, cell therapy, gene therapy, RNA therapeutics, peptides and proteins, radiopharmaceuticals, vaccines, and microbiome drugs. Our 79+ cell and gene therapy consultants and 46+ oncology MDs reflect particularly deep coverage in high-demand areas.

Every engagement is managed by Alacrita's core team, who are responsible for scope, timeline, and deliverable quality. The client's contract is with Alacrita, not with individual consultants. The core team reviews all work product, manages client communication, and ensures continuity. If circumstances change or different expertise is needed mid-project, Alacrita handles it. This is fundamentally different from staffing agencies or placement firms where you manage the consultant directly.

No. Alacrita does not offer one-hour consultations. Our consultants are engaged on defined project assignments where they can contribute materially to specific deliverables or outcomes. This project-based approach ensures deeper engagement, accountability, and better results than brief ad-hoc calls. Alacrita is a consulting firm, not an expert network.